Examkin

Question

Difficulty: MediumHemodynamic and Coagulation Processes

A 45-year-old male patient is assessed on the surgical ward 6 days after undergoing an open reduction and internal fixation of a right femur fracture. He has been receiving prophylactic doses of subcutaneous unfractionated heparin since the operation. The patient now reports a new, deep ache in his left calf. Physical examination demonstrates unilateral left lower extremity edema with localized tenderness. A duplex ultrasonography reveals an acute, occlusive thrombus in the left popliteal vein. Laboratory testing shows a platelet count of 105,000/mm³, a significant decrease from his preoperative baseline of 260,000/mm³. His prothrombin time and activated partial thromboplastin time are within normal limits. Which of the following best describes the molecular mechanism responsible for this patient's current presentation?

  1. A
    Widespread activation of the coagulation cascade resulting in systemic consumption of clotting factors and platelets
  2. B
    Transient hypercoagulable state caused by the rapid depletion of a vitamin K-dependent endogenous anticoagulant
  3. Binding of immunoglobulin G to a complex of platelet factor 4 and a therapeutic glycosaminoglycanAnswer
  4. D
    Inhibitory autoantibodies directed against a metalloproteinase responsible for cleaving von Willebrand factor multimers
  5. E
    Antibody-mediated destruction of platelets via splenic macrophage phagocytosis without concurrent platelet activation

Answer

Binding of immunoglobulin G to a complex of platelet factor 4 and a therapeutic glycosaminoglycan
The correct answer accurately outlines the pathophysiology of Heparin-Induced Thrombocytopenia (HIT). In HIT, the administration of a therapeutic glycosaminoglycan (heparin) leads to the formation of immunogenic complexes with endogenous platelet factor 4 (PF4). The immune system mounts an IgG antibody response against these complexes. The resulting IgG-PF4-heparin complexes bind to FcγRIIa receptors on platelet surfaces, causing robust platelet activation, aggregation, and the release of procoagulant microparticles. This cascade results in a highly thrombogenic state (manifesting as a deep vein thrombosis in this patient) and a concurrent drop in platelet count as they are consumed in the thrombi.

Step-by-Step Solution

1
Analyze the clinical presentation and timeline.
The patient developed a >50% drop in platelets and a new venous thrombosis 6 days after starting unfractionated heparin.
Establishing the classic '4T's' criteria components (Thrombocytopenia, Timing, Thrombosis, and no other cause) points toward a specific drug-induced complication.
2
Identify the primary diagnosis.
The clinical picture is diagnostic for Heparin-Induced Thrombocytopenia (HIT) Type 2.
HIT is characterized by a paradoxical prothrombotic state combined with a consumptive thrombocytopenia following recent heparin exposure.
3
Determine the underlying pathophysiology of the diagnosis.
HIT is an immune-mediated reaction where the body forms IgG autoantibodies against a complex of endogenous Platelet Factor 4 (PF4) and exogenous heparin.
Understanding the precise molecular trigger is necessary to select the correct underlying mechanism.
4
Connect the molecular trigger to the clinical findings.
These IgG antibodies bind to the PF4-heparin complex and cross-link Fc receptors on the platelet surface, causing widespread platelet activation, subsequent thrombosis, and consumption of circulating platelets.
This fully explains both the new deep vein thrombosis and the falling platelet count seen in the patient.

Key Concept

The pathophysiology of Heparin-Induced Thrombocytopenia (HIT) Type 2 involves the formation of IgG antibodies against the heparin-Platelet Factor 4 (PF4) complex, leading to widespread platelet activation and paradoxical thrombosis.
Estimated Time:1m 30s
Rate this question

Topics

Hemodynamic and Coagulation Processes

More questions from this topic